... responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. 2026 Upper tract urothelial carcinoma Perioperative therapy Neoadjuvant chemotherapy Adjuvant immunotherapy ctDNA Urothelial carcinoma...

...Levent Ozcan; Emre Can Polat; Caner Baran; Ahmet Boylu; Mustafa Erkoc; Alper Otunctemur Introduction: The main challenge to the optimal use of neoadjuvant chemotherapy (NAC) is the difficulty in selecting patients who may or may not benefit from NAC. Our aim in this study was to investigate whether...

... the adaption of neoadjuvant chemotherapy (NAC) in patients with muscle-invasive bladder cancer (MIBC) in Germany, Austria, and Switzerland and especially underlying reasons for potential low adherence to guidelines. Methods: We conducted a non-validated survey among 336 urologic departments in Germany, Austria...

... (a), common number of administered cycles of NAC and AC (b), and chemotherapy regimen usually used in cisplatin ineligible patients (c). AC, adjuvant chemotherapy; NAC, neoadjuvant chemotherapy. Fig. 1. Utilization of NAC and AC (a), common number of administered cycles of NAC and AC (b), and chemotherapy...

..., adequate follow-up is needed to assess the ability of neoadjuvant chemotherapy to improve the prognosis of patients with locally advanced urothelial cancer of the upper urinary tract. 19 12 1994 23 01 1995 3 2 2010 © 1995 S. Karger AG, Basel 1995 Copyright / Drug Dosage...